SANDOSTATIN LAR
 |
|
|
Package(a):
VIALS: 1 x 10 mg (2 vehicle ampoules + 1 injection set).
Dosage(a):
By deep intragluteal injection. See prescribing information for full details.
Prescribing Restrictions:
Package(b):
VIALS: 1 x 20 mg (2 vehicle ampoules + 1 injection set).
Dosage(b):
By deep intragluteal injection. See prescribing information for full details.
Prescribing Restrictions:
Package(c):
VIALS: 1 x 30 mg (2 vehicle ampoules + 1 injection set).
Dosage(c):
By deep intragluteal injection. See prescribing information for full details.
Prescribing Restrictions:
Package(d):
PREFILLED SYRINGE (with solvent for parenteral use): 1 x 10 mg + 2 needles.
Dosage(d):
See prescribing information for full details.
Prescribing Restrictions: None
Package(e):
PREFILLED SYRINGE (with solvent for parenteral use): 1 x 20 mg + 2 needles.
Dosage(e):
See prescribing information for full details.
Prescribing Restrictions: None
Package(f):
PREFILLED SYRINGE (with solvent for parenteral use): 1 x 30 mg + 2 needles.
Dosage(f):
See prescribing information for full details.
Prescribing Restrictions: None
Indications:
Treatment of patients with acromegaly who are adequately controlled on S.C. treatment with Sandostatin; in whom surgery or radiotherapy is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective.
Treatment of patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumors in whom symptoms are adequately controlled on S.C. treatment with Sandostatin.
Carcinoid tumors with features of the carcinoid syndrome, VIPomas, glucagonomas, gastrinomas/Zollinger-Ellison syndrome, insulinomas, for pre-operative control of hypoglycemia and for maintenance therapy, GRFomas.
Contra-Indications:
Hypersensitivity to octreotide or any of components of the formulation.
Special Precautions:
As GH-secreting pituitary tumors may sometimes expand, causing serious complications, it is essential that all patients be carefully monitored. If evidence of expansion appears, alternative procedures are advisable. Development of gallstones has been reported in 15-30% of long-term recipients of S.C. Sandostatin. Ultrasonic examination of the gallbladder before and at about 6-monthly intervals during therapy is however recommended. In patients with concomitant type I diabetes mellitus, treatment is likely to affect glucose regulation, and insulin requirements may be reduced. In non-diabetics and type II diabetics with partially intact insulin reserves, administration may result in increases in post-prandial glycemia. Glucose tolerance and antidiabetic treatment should therefore be monitored. In patients with insulinomas, octreotide may increase the depth and prolong the duration of hypoglycemia. Patients should be closely monitored.
Pregnancy and lactation: Should be given only under compelling circumstances.
Side Effects:
Gallstone formation. Anorexia, nausea, vomiting, crampy abdominal pain, abdominal bloating, flatulence, loose stools, diarrhea, steatorrhea. Hyperglycemia, hypoglycaemia.
Drug Interactions:
Cyclosporin, cimetidine, hypoglycemics. Bromocriptine, beta blockers, calcium channel blockers, agents to control fluid and electrolyte balance.
